REZZAYO

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Lithuania, United Kingdom, United States

Active ingredients

The drug REZZAYO contains one active pharmaceutical ingredient (API):

1 Rezafungin UNII W1U1TMN677 - REZAFUNGIN ACETATE

Rezafungin selectively inhibits fungal 1,3-β-D-glucan synthase. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall which is not present in mammalian cells. Inhibition of 1,3-β-D-glucan synthesis results in rapid and concentration-dependent fungicidal activity in Candida species (spp.). Read about Rezafungin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
REZZAYO Powder for solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR
REZZAYO Powder for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J02AX08		J Antiinfectives for systemic use → J02 Antimycotics for systemic use → J02A Antimycotics for systemic use → J02AX Other antimycotics for systemic use
Discover more medicines within J02AX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3063013
Country: FR	Base de données publique des médicaments	Identifier(s): 67183313
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1098537
Country: US	FDA, National Drug Code	Identifier(s): 70842-240